ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is proud to announce that the French region of Aquitaine (around Bordeaux) has awarded ImmuPharma’s subsidiary Ureka a non-refundable grant of approx. €400,000 EUR to develop Ureka’s Urelix technology. The Urelix technology is a way to mimic natural peptides having a…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has conditionally, raised approximately £3.4 million. This is principally from ImmuPharma’s long standing shareholder Aviva Investors through a placing of 6,340,000 new ordinary shares of 10p each in the Company, at a price of 53 pence per share,…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2014. KEY HIGHLIGHTS • LupuzorTM – Announced separately today – Phase III activities of lead compound Lupuzor™ will soon commence: Following advanced discussions and after completing detailed due diligence…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is delighted to announce that Phase III activities of its lead compound Lupuzor™ will soon commence. Following advanced discussions and after completing detailed due diligence with a potential partner, ImmuPharma has started the preparatory steps for Lupuzor’s™ pivotal phase III clinical…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed. A summary of proxy votes is shown in the table below. Please also refer to the ‘Notice of Meeting’ in the Report & Accounts –…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is delighted to provide further details on its activities in the Bordeaux region of France, working closely with one of its key collaborators at the CNRS*, ImmuPharma’s longstanding research partner, accessing novel drug research in the area of peptides. One key…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is delighted to announce that the US Patent and Trademark Office has granted a notice of allowance for an “optically pure” version of ImmuPharma’s Nucant family. A similar grant has been obtained from the EU, Japanese and Australian patent offices. The…

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2013. Key Highlights: LupuzorTM Discussions continue with potential partners in parallel to discussions with Contract Research Organisations and alternative financing organisations for LupuzorTM’s pivotal Phase III programme…

ImmuPharma PLC (AIM:IMM) (the “Company”)  the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2013 will be posted to shareholders today. The Annual Report is available, in electronic form, for download on the Company’s website www.immupharma.co.uk. The Company’s Annual General Meeting will be held…

ImmuPharma PLC (LSE: IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, provides a summary of the presentation given by Dr. Slyviane Muller at the European Lupus Conference which recently took place in Athens, Greece. The “European Lupus Meeting” is a major forum for all people interested in the disease: with approximately…